US Pharma MarketingDraig nets $65M to advance depression drug aimed at rebuilding synapses
Draig Therapeutics closes an oversubscribed $65M Series B, advancing its depression drug DT-101 through Phase 2 and toward potential Phase 3. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…
Draig Therapeutics has secured $65 million in an oversubscribed Series B raise to advance a pipeline of neuropsychiatry drugs, including its lead depression program designed to modulate the AMPA receptor.
The ...
Source: Endpoints News